您要查找的是不是：
- Epoetin Epo 促红细胞生成素[抗贫血药]
- The EPO also performed searches under the PCT. EPO也在PCT的指导下执行检索工作。
- The relative Epo deficieny in RA with ACD. RA伴ACD者体内Epo相对不足；
- Then in 2004 the EPO revoked the patent entirely. 最终，在2004年，欧洲专利局撤消了它的专利权。
- Since then,tests to pinpoint EPO misuses have been developed. 从那时起，人们又发明了检测EPO滥用的技术。
- Since then, tests to pinpoint EPO misuses have been developed. 从那时起，人们又发明了检测EPO滥用的技术。
- The production of EPO raw material belongs to the biology ferment. EPO原料生产经过数次的试生产，就是达不到标准；
- The drug erythropoietin (EPO) provides a good example. 药物促红细胞生长素(EPO)就是一个很好的例子。
- EEC did not correlate with PV patients' serum Epo levels( r=0.518,P =0.125). EEC与血清Epo水平无相关性 (r =0 .;5 18;P =0
- The EPO has only three official languages: English, French and German. 欧洲专利局的官方语言只有英语，法语及德语。
- Erythropoietin ( EPO ) is widely used in clinical and basic studies. 红细胞生成素(EPO)在临床和基础研究中应用广泛。
- The most frequent causes of PTA were erythropoietin (EPO) and iron deficiency. 导致PTA最常见的原因是红细胞生成素（EPO）和缺铁。
- In all patients, neutralizing antibody titer slowly decreased when epoetin treatment was discontinued. 当治疗被终止后，抑制性抗体的浓度也逐渐下降。
- This open-label, multicenter, single-arm study investigated the efficacy of administration of 20,000 IU of epoetin alfa once every 2 wk as initiation therapy in these patients. 这个标签公开，多中心，单一目的的试验观察在起始治疗阶段每两周注射1次重组人红细胞生成素20,000IU的效果。
- Patients receied 20,000 IU of epoetin alfa subcutaneously eery 2 wk for up to 27 wk, with dosage adjustments permitted after 4 wk of treatment. 这个标签公开，多中心，单一目的的试验观察在起始治疗阶段每两周注射1次重组人红细胞生成素20,000IU的效果。
- Patients received 20,000 IU of epoetin alfa subcutaneously every 2 wk for up to 27 wk, with dosage adjustments permitted after 4 wk of treatment. 病人每两周接受1次重组人红细胞生成素皮下注射，直到第27周，在用药第4周后允许对用药量进行调整。
- In 12 patients, the neutralizing antibodies recognized only a conformational epitope requiring proper folding of the epoetin protein. 在所有的患者中。
- However, the prospect of adding EPO genes to an athlete's own DNA would bypass such tests. 但是，将来的技术可以在运动员自身的DNA中植入EPO基因，从而使运动员逃过这种检测。
- This open-label, multicenter, single-arm study inestigated the efficacy of administration of 20,000 IU of epoetin alfa once eery 2 wk as initiation therapy in these patients. 这个标签公开，多中心，单一目的的试验观察在起始治疗阶段每两周注射1次重组人红细胞生成素20,000IU的效果。
- The results showed that after administration of phosphate-buffered epoetin alfo, the large majority (55 responses: 68.75%) reported no or very mild pain after SC administration. 在对疼痛的主观感觉评估方面，46.;25%25的柠檬酸盐红血球生成素注射反应为感觉不痛或轻微疼痛，68
